We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer.
- Authors
Fruscio, Robert; Garbi, Annalisa; Parma, Gabriella; Lissoni, Andrea Alberto; Garavaglia, Daniela; Bonazzi, Cristina Maria; Dell'Anna, Tiziana; Mangioni, Costantino; Milani, Rodolfo; Colombo, Nicoletta
- Abstract
This randomized, open label, phase III clinical trial (1988–1992) compared the efficacy and safety of a dose-dense regimen of single-agent cisplatin with a standard 3-weekly schedule in first-line chemotherapy for advanced epithelial ovarian cancer. Two hundred eighty-five patients were randomly assigned to the experimental dose-dense arm (cisplatin 50 mg/m2 weekly × nine cycles) or to the control (standard treatment) arm (cisplatin 75 mg/m2, administered on day 1 every 21 days × six cycles). The primary outcome was progression-free survival (PFS). Secondary outcomes were overall survival (OS), overall response to chemotherapy, and toxicity. Toxicity and response to treatment were compared with the χ2 test using trend or exact correction. PFS and OS were estimated by Kaplan–Meier analyses and treatment hazard ratios (HRs) with the Cox proportional hazards model. All statistical tests were two-sided. After a median follow-up of 16.8 years, no differences were observed between the two treatments in PFS (experimental arm: 17.2 months; control arm: 18.1 months; HR = 1.08, 95% confidence interval [CI] = 0.83 to 1.40; P = .57) and in OS (experimental arm: 35 months; control arm: 32 months; HR = 0.97, 95% CI = 0.75 to 1.26; P = .97). Thus, increasing dose intensity of cisplatin does not improve PFS or OS compared with standard chemotherapy.
- Subjects
CLINICAL trials; CANCER hormone therapy; OVARIAN cancer; DRUG therapy; CANCER treatment
- Publication
JNCI: Journal of the National Cancer Institute, 2011, Vol 103, Issue 4, p347
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djq530